Glatiramer Publication Examines PIRA in MS Platform Treatments

On October 5, 2026, a new publication involving glatiramer appeared in the Journal of Neurology. The article is titled "Incidence of Progression Independent of Relapse Activity (PIRA) under platform disease-modifying treatment in multiple sclerosis." This is listed as a publication event, not a clinical trial result. The title indicates the paper addresses PIRA incidence among patients receiving platform disease-modifying treatments for multiple sclerosis, a category that includes glatiramer. No findings, outcomes, or efficacy data from the publication were provided alongside this announcement. No details on study design, patient numbers, or specific results were included in the available event information. Glatiramer remains an approved treatment. This entry reflects only the existence and bibliographic details of the new publication. Readers interested in the specific content, methodology, or conclusions of this paper should consult the full text through the Journal of Neurology or the linked PubMed record. For additional background on glatiramer, including its approved uses and general profile, readers can refer to the compound overview.